Analyst Rating Update on Heat Biologics (HTBX)

Heat Biologics (HTBX) : The consensus on Heat Biologics (HTBX) based on 2 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

Heat Biologics (HTBX) stock is expected to deviate a maximum of $3.71 from the average target price of $5.38 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $8 and the most muted being $3.

For the current week, the company shares have a recommendation consensus of Buy. Also, Roth Capital initiates coverage on Heat Biologics (NASDAQ:HTBX). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Roth Capital announces a current price target of $2.75 per share. The rating by the firm was issued on June 20, 2016.


Heat Biologics (NASDAQ:HTBX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.12 and $1.10 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.33. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.13, notching a gain of 4.63% for the day. The total traded volume was 6,414,158 . The stock had closed at $1.08 on the previous day.

Heat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patients own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.